Xenon Pharmaceuticals Inc.

Publicly traded biopharmaceutical company (NASDAQ: XENE). Developer of azetukalner (XEN1101), a Kv7 potassium channel opener. Filed its FDA NDA for focal epilepsy in Sep 2026, while separately pausing enrollment in its MDD/bipolar depression trials the same month over neuropsychiatric adverse events. No tinnitus program.